<DOC>
	<DOCNO>NCT02117830</DOCNO>
	<brief_summary>This Phase I , single-site , randomize , double-blinded , double-dummy , placebo- positive-controlled , 4-period crossover study evaluate effect two dose level Androxal cardiac repolarization . Baseline ECGs obtain prior dosing Period ECGs obtain expect peak plasma concentration Androxal positive control . In Treatment Period subject admit Clinical Research Unit study drug administer three ( 3 ) daily single dos . Treatment Periods separate washout least 7 day Periods .</brief_summary>
	<brief_title>A Thorough QT/QTc Study Assess Effects Androxal Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Generally healthy male determine history physical examination 2 . Between age 18 60 , inclusive 3 . Clinical laboratory test result within normal reference range investigative site result acceptable deviation judge principal investigator clinically significant 4 . Vital sign ( 5 minute rest supine position ) Systolic blood pressure ( SBP ) 90140 mmHg , Diastolic blood pressure ( DBP ) 5090 mmHg , Pulse 45100 bpm Note : subject vital sign outside range may eligible study Investigator feel result clinically significant impact study conduct . 5 . Body mass index ( BMI ) ≥25 ≤42 kg/m2 Screening 6 . Are reliable willing available duration study , abide policy procedures clinical trial unit 7 . Have give write informed consent 8 . Subject must able speak , read understand English Spanish willing able provide write informed consent English Spanish Institutional Review Board ( IRB ) approve form prior initiation study procedure . Subject must sign date write informed consent form ( ICF ) undergo study related activity , include discontinuation prohibit medication . 1 . Repros employee investigative site personnel immediate family 2 . Participation clinical trial within past 30 day receipt investigational agent study treatment within 30 day 5 halflives , whichever longer , prior Screening 3 . Known hypersensitivity Clomid 4 . Known allergy moxifloxacin 5 . Abnormal electrocardiogram , option repeat finding , opinion Investigator and/or Sponsor may interfere aspect study conduct interpretation result include : abnormality cardiac rhythm sinus arrhythmia QTcF &gt; 450 msec QTcF &lt; 300 msec PR interval &gt; 200 msec QRS &gt; 110 msec abnormal T wave morphology impair ability measure QT interval reliably 6 . History congenital long QT syndrome know history QTc interval prolongation family history congenital long QT syndrome 7 . Evidence significant cardiac disease , example , arrhythmia unexplained syncope within last year 8 . History myocardial infarction , unstable angina , symptomatic heart failure , ventricular dysrhythmia , 9 . History thrombophlebitis , thromboembolic disorder cerebrovascular accident 10 . Evidence significant respiratory hepatic disease 11 . Use cigarette tobacco product within 2 week prior Screening participate study 12 . Use medication acetaminophen aspirin ( prescription overthecounter ) , herbal tea , energy drink , supplement , within 5 day dose ( prior first dose study medication ) , exception approve Investigator Sponsor 13 . Use drug abuse and/or positive finding drug screen 14 . Known active infection HIV hepatitis B C .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>To determine</keyword>
	<keyword>effect</keyword>
	<keyword />
	<keyword>daily</keyword>
	<keyword>oral dos</keyword>
	<keyword>Androxal</keyword>
</DOC>